Literature DB >> 29188737

Eruptive cherry angiomas developing in a patient treated with ramucirumab.

Pablo Espinosa Lara1, Camino Medina-Puente2, Alejandro Riquelme Oliveira3, José Jiménez-Reyes4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29188737     DOI： 10.1080/0284186X.2017.1410287

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  3 in total

1.  Anti-PD1 'SHR-1210' aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement.

Authors:  William J J Finlay; James E Coleman; Jonathan S Edwards; Kevin S Johnson
Journal:  MAbs       Date:  2018-12-12       Impact factor: 5.857

2.  A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia.

Authors:  Jason D Lickliter; Hui K Gan; Mark Voskoboynik; Surein Arulananda; Bo Gao; Adnan Nagrial; Peter Grimison; Michelle Harrison; Jianjun Zou; Lianshan Zhang; Stacey Luo; Michael Lahn; Howard Kallender; Andrea Mannucci; Catello Somma; Katherine Woods; Andreas Behren; Pablo Fernandez-Penas; Michael Millward; Tarek Meniawy
Journal:  Drug Des Devel Ther       Date:  2020-03-18       Impact factor: 4.162

3.  Osimertinib and Ramucirumab Induced Pyogenic Granulomas: A Possible Synergistic Effect of Dual Oncologic Therapy.

Authors:  Robert P Daze; Jewell Dinkins; Matthew H Mahoney
Journal:  Cureus       Date:  2021-05-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.